Immune checkpoint inhibitors-associated acute kidney injury: a systematic review and meta-analysis of incidence, kidney recovery, and recurrent risk.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are widely used in cancer therapy but can cause adverse events, including acute kidney injury (AKI). The incidence of ICI-associated AKI (ICI-AKI) varies across studies, and while steroids may aid in kidney recovery, their full effects require further investigation. Additionally, the risk of recurrent AKI with ICI rechallenge remains uncertain. This study assesses the incidence of ICI-AKI, evaluates steroid efficacy, and examines the risk of recurrent AKI after ICI-AKI.

Methods

A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted through May 2024. Outcomes included the incidence of ICI-AKI, kidney recovery after steroid therapy, and the risk of recurrent AKI with ICI rechallenge. A random-control mode

SUBMITTER: Ho CW 

PROVIDER: S-EPMC12484524 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature